ClinicalTrials.gg
RecruitingNCT06908200Updated Apr 3, 2025

Effect of Radiofrequency in Women With Chronic Pelvic Pain With an Associated Myofascial Syndrome Versus Myofascial Therapy and no Treatment

An interventional study of Radiofrequency therapy and myofascial manual therapy in Chronic Pelvic Pain, sponsored by Hospital Clinic of Barcelona. Recruiting at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by Hospital Clinic of Barcelona · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Registered 2 years 10 months after the study started (first participant enrolled May 2022, registered Mar 2025).
  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Pelvic Pain with a site in Spain — 6 open to participants now, 6 under way, none of them phase 3. Pelvic Pain · Spain.

Planned enrollment
9th of 22
80 · median 69
Started
2022
the only one that year
No phase
16 of 27
5 open now
Registered
21st of 27
by date
Lead sponsor
2 of 27
Hospital Clinic of Barcelona

Among the 27 studies in Pelvic Pain with a site in Spain, this one is the 9th largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2022, is one of 16 with no phase, and was the 21st registered.

Pelvic Pain

377 studies on the registry are indexed under Pelvic Pain; 91 are open to participants now.

Browse Pelvic Pain studies →

Open to participants now

6 of the 27 studies in Pelvic Pain with a site in Spain are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 61 Pelvic Pain studies recruiting now, 22 (36%) set no upper age limit and 37 (61%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Pelvic Pain with a site in Spain, or all of them as a file.
02

Study summary

A randomised clinical trial is being conducted in the Gynecology Department of the Hospital Clinic de Barcelona in women presenting chronic pelvic pain syndrome due to a myofascial cause which is over a 4 score in the VAS scale and not related to an obstetric injury. This study presents 4 groups; two groups receive 8 radiofrequency sessions, one group receives 8 sessions of myofascial release therapy (MRT) and the last group receives no treatment at all (NT). The two RF groups have been divided into a RF intervention group (RFIG) and a RF control group (RFCG) which receives sham treatment. The RF groups are double-blinded. Other than RF, both groups perform daily Thiele massage at home. The sessions last for 20 minutes and take place once a week during 8 weeks.

The main variable evaluated is the level of pain during the muscular assessment carried out by an expert pelvic floor physical therapist using the Verbal numeric Scale in the first session and at the end of the 8 sessions. Secondary variables are: sexual function (throughout FSFI questionnaire), pain catastrophizing (ECD), quality of life (EQ5D), anxiety and depression (HADS), central sensitization (CSI) as well as other pelvic floor dysfunction symptoms (PFDI).

03

Conditions studied

  • Chronic Pelvic Pain

Browse trials for

Keywords

  • chronic pelvic pain
  • myofascial syndrome
  • radiofrequency
  • manual therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age
  • Presenting with pelvic pain persisting for at least 6 months
  • Diagnosed with myofascial syndrome of the pelvic floor muscles (PFM) by a specialist based on physical assessment
  • Presenting with pelvic pain intensity greater than 4 on the Visual Analog Scale (VAS) in the last 3 months
  • Agreed to sign the form.

Exclusion criteria

Exclusion criteria included the following:

  • Patients who were pregnant
  • Postpartum patients who had given birth within the last year
  • Patients with a history of vulvovaginal pathology
  • for the use of radiofrequency: metal implants or active infection
  • Patients with a history of pelvic cancer, including those who had undergone chemotherapy, radiotherapy, and/or brachytherapy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    ON RF

    Application of the technique in the intervention group (activated resistive capacitive monopolar radiofrequency therapy): the intervention group 1 will receive treatment with activated RF, with the electrode at a medium intensity for 20 minutes per session during a total of 8 sessions, held weekly.

    Device: Radiofrequency therapy

  • Sham comparator
    OFF RF

    Application of the technique in the intervention group (activated resistive capacitive monopolar radiofrequency therapy): the CONTROL group 2 will receive treatment with activated RF, with the electrode for 20 minutes per session during a total of 8 sessions, held weekly.

    Device: Radiofrequency therapy

  • Active comparator
    MYOFASCIAL MANUAL THERAPY

    Application of the technique in the intervention group 2 (MYOFASCIAL MANUAL THERAPY): the intervention group 2 will receive treatment for 20 minutes per session during a total of 8 sessions, held weekly.

    Other: myofascial manual therapy

  • No intervention
    NO TREATMENT

    Patients in waiting list, pending treatment will not receive treatment but symptoms will be monitored after 6 months

Interventions

  • DeviceRadiofrequency therapy

    Radiofrequency or myofascial manual therapy sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home

  • Othermyofascial manual therapy

    Myofascial manual therapy sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home

06

What researchers measure

Primary outcomes

  1. Pain Level

    Pain Level using the Verbal Numeric Scale (VNS). The scores go from 0 (lowest) to 10 (highest)

    Time frame: 8 weeks

Secondary outcomes

  1. Sexual function

    Sexual function using the female sexual function index. The score ranges from 2 (severe) to 36 (no sexual disfunction)

    Time frame: 8 weeks

  2. Quality of life (QoL)

    Quality of life using the EuroQuality of life-5Dimensions (EQ5D. Ranges from -0.59 (lowest QoL) and 1 (highest)

    Time frame: 8 weeks

  3. Pain catastrophizing

    Using the pain catastrophizing scale (PCS).Ranges from 0 to 52 where higher scores indicate a greater degree of pain catastrophizing. A total score of \>30 represents a clinically significant level of pain catastrophization

    Time frame: 8 weeks

  4. Anxiety and depression

    Anxiety and depression using the Hospital Anxiety and depression Scale (HADS). Generally, scores of 0 to 7 on this questionnaire are considered to be normal, scores of 8 to 10 indicate mild symptoms, 11 to 14 indicate moderate symptoms, and 15 to 21 indicate severe symptoms

    Time frame: 8 weeks

  5. Central sensitization

    Using the central sensitization index (CSI). Ranging from 0-100, \>40 is the cutoff for pain sensitization

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Jun 2025, 37 months after the start.

Of 110 non-industry interventional studies with no phase under Pelvic Pain, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 37 months is above that.

Counting every sponsor, half of 114 studies reached it within 17 months; a quarter within 5 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2025
First posted
Apr 3, 2025
StartActual
May 10, 2022
Primary completionEst.
Jun 10, 2025
CompletionEst.
Jun 15, 2025
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06908200
Responsible party
Carla Box (Principal Investigator, Hospital Clinic of Barcelona) — Principal investigator
First posted
Apr 3, 2025
Start date
May 10, 2022
Primary completion
Jun 10, 2025 (estimated)
Completion
Jun 15, 2025 (estimated)
Last update
Apr 3, 2025

Study contacts

Carla Box, PT, MSc
Contact
cebox@clinic.cat
+34932275300

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion